These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18343831)

  • 1. Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease.
    Mbulawa ZZA; Williamson AL; Stewart D; Passmore JS; Denny L; Allan B; Marais DJ
    J Gen Virol; 2008 Apr; 89(Pt 4):910-914. PubMed ID: 18343831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia.
    Passmore JA; Marais DJ; Sampson C; Allan B; Parker N; Milner M; Denny L; Williamson AL
    J Med Virol; 2007 Sep; 79(9):1375-80. PubMed ID: 17607771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
    Mboumba Bouassa RS; Péré H; Gubavu C; Prazuck T; Jenabian MA; Veyer D; Meye JF; Touzé A; Bélec L
    PLoS One; 2020; 15(5):e0233084. PubMed ID: 32421735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology.
    Rocha-Zavaleta L; Pereira-Suarez AL; Yescas G; Cruz-Mimiaga RM; Garcia-Carranca A; Cruz-Talonia F
    Viral Immunol; 2003; 16(2):159-68. PubMed ID: 12828867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
    Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
    Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study.
    Bierl C; Karem K; Poon AC; Swan D; Tortolero-Luna G; Follen M; Wideroff L; Unger ER; Reeves WC
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S262-8. PubMed ID: 16229879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population.
    Marais DJ; Sampson C; Jeftha A; Dhaya D; Passmore JA; Denny L; Rybicki EP; Van Der Walt E; Stephen LX; Williamson AL
    BMC Infect Dis; 2006 Jun; 6():95. PubMed ID: 16762074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two types of sponges used to collect cervical secretions and assessment of antibody extraction protocols for recovery of neutralizing anti-human papillomavirus type 16 antibodies.
    Kemp TJ; Hildesheim A; Falk RT; Schiller JT; Lowy DR; Rodriguez AC; Pinto LA
    Clin Vaccine Immunol; 2008 Jan; 15(1):60-4. PubMed ID: 18032596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical human papillomavirus (HPV) infection and HPV type 16 antibodies in South African women.
    Marais DJ; Constant D; Allan B; Carrara H; Hoffman M; Shapiro S; Morroni C; Williamson AL
    J Clin Microbiol; 2008 Feb; 46(2):732-9. PubMed ID: 18077644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
    Jain BB; Adhikary T; Sadhukhan PC; Nandi A
    J Cancer Res Ther; 2021; 17(6):1462-1467. PubMed ID: 34916378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus (HPV) and Epstein-Barr virus (EBV) cervical infections in women with normal and abnormal cytology.
    Szkaradkiewicz A; Wal M; Kuch A; Pieta P
    Pol J Microbiol; 2004; 53(2):95-9. PubMed ID: 15478354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of antibody to E2 protein of human papillomavirus and p16
    Chuerduangphui J; Pientong C; Swangphon P; Luanratanakorn S; Sangkomkamhang U; Tungsiriwattana T; Kleebkaow P; Burassakarn A; Ekalaksananan T
    Med Oncol; 2018 May; 35(6):93. PubMed ID: 29744680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy.
    Monroy OL; Aguilar C; Lizano M; Cruz-Talonia F; Cruz RM; Rocha-Zavaleta L
    J Clin Virol; 2010 Jan; 47(1):43-8. PubMed ID: 19906557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix.
    Shah KV; Viscidi RP; Alberg AJ; Helzlsouer KJ; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):233-7. PubMed ID: 9107427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding HLA-G driven journey from HPV infection to cancer cervix: Adding missing pieces to the jigsaw puzzle.
    Aggarwal R; Sharma M; Mangat N; Suri V; Bhatia T; Kumar P; Minz R
    J Reprod Immunol; 2020 Nov; 142():103205. PubMed ID: 33099242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.
    Velentzis LS; Sitas F; O'Connell DL; Darlington-Brown J; Egger S; Sinha R; Banks E; Frazer IH; Canfell K
    BMC Infect Dis; 2014 Dec; 14():3861. PubMed ID: 25528152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions?
    Ochi H; Matsumoto K; Kondo K; Oki A; Furuta R; Hirai Y; Yasugi T; Takatsuka N; Maeda H; Mitsuhashi A; Fujii T; Kawana K; Iwasaka T; Yaegashi N; Watanabe Y; Nagai Y; Kitagawa T; Kanda T; Yoshikawa H;
    J Med Virol; 2012 Jul; 84(7):1128-34. PubMed ID: 22585732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
    Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
    J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.
    Harper DM; Franco EL; Wheeler C; Ferris DG; Jenkins D; Schuind A; Zahaf T; Innis B; Naud P; De Carvalho NS; Roteli-Martins CM; Teixeira J; Blatter MM; Korn AP; Quint W; Dubin G;
    Lancet; 2004 Nov 13-19; 364(9447):1757-65. PubMed ID: 15541448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions.
    Rocha-Zavaleta L; Ambrosio JP; Mora-Garcia ML; Cruz-Talonia F; Hernandez-Montes J; Weiss-Steider B; Ortiz-Navarrete V; Monroy-Garcia A
    J Gen Virol; 2004 Sep; 85(Pt 9):2643-2650. PubMed ID: 15302958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.